Rifabutin is under clinical development by Bioversys and currently in Phase I for Ventilator Associated Pneumonia (VAP). According to GlobalData, Phase I drugs for Ventilator Associated Pneumonia (VAP) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rifabutin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rifabutin is under development for the treatment of Carbapenem Resistant Acinetobacter baumannii (CRAB) ventilator associated bacterial pneumonia, hospital acquired bacterial pneumonia and bloodstream infections. It is administered by intravenous route.
Bioversys is a biotechnology company that researches and develops small molecules which turn off drug resistance against existing antibiotics. The company product pipeline includes BV100 novel MoA, BVL-GSK098 novel potentiator MoA, BV200 novel anti-virulence MoA, BV300 – novel class. Its services includes Research and Development and Clinical Trials. It develops a pipeline product for the treatment of nosocomial infection. Bioversys addresses the medical need for new treatments against life-threatening bacterial infections and for the resistance of bacterial strains against existing antibiotics. The company also conducts research on nosocomial infections and tuberculosis. Bioversys is headquartered in Basel, Basel-Stadt, Switzerland.
For a complete picture of Rifabutin’s drug-specific PTSR and LoA scores, buy the report here.